AGA wants to let our research members know about a funding opportunity for projects advancing scientific knowledge about inequities in the care of patients with primary biliary cholangitis (PBC), including racial/ethnic disparities.
Intercept Pharmaceuticals will provide financial support of up to $150,000 per pilot project selected – with preference given to projects that can be completed within 12-18 months. They are looking for projects that gather and leverage real-world data representative of current patient care in PBC. Investigators must reside and conduct the research in the United States. The number of awards funded will depend on available funding and the number of well-scored applications.
Areas of programmatic interest
- Description and investigation of potential barriers and disparities impacting a timely PBC disease diagnosis
- Evaluation of potentially relevant differences in monitoring and treatment per recommended guidelines across populations
- Examination of potentially relevant differences in PBC-related outcomes (short- and/or long-term) across populations
To request a concept proposal form or to submit a research proposal, please contact the Intercept Investigator-initiated Research (IIR) email at [email protected].
The application window will close on Nov. 30, 2022.
If you wish to discuss the aims of your research proposal further, please contact your local Intercept Medical Science Liaison, or request a meeting with an Intercept Medical Affairs group member by emailing [email protected]. You may also send questions to [email protected].